Drug Profile
Darovasertib - IDEAYA Biosciences
Alternative Names: IDE 196; LXS-196; NVP-LXS-196Latest Information Update: 09 Jan 2024
Price :
$50
*
At a glance
- Originator Novartis
- Developer IDEAYA Biosciences; Novartis; St Vincents Hospital, Sydney
- Class Amides; Amines; Antineoplastics; Fluorinated hydrocarbons; Piperidines; Pyrazines; Pyridines; Skin disorder therapies; Small molecules
- Mechanism of Action Protein kinase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Uveal melanoma
- Phase II Colorectal cancer; Malignant melanoma; Solid tumours
- Preclinical Neurological disorders; Nevus
Most Recent Events
- 31 Oct 2023 Phase-II/III clinical trials in Uveal melanoma (Combination therapy, First-line therapy, Metastatic disease) in Canada (PO) (NCT05987332)
- 20 Oct 2023 Efficacy and adverse events data from a phase II trial in Uveal Melanoma presented by IDEAYA Biosciences at 48th European Society for Medical Oncology Congress (ESMO-2023)
- 17 Oct 2023 IDEAYA Biosciences expects accelerated approval for darovasertib in Uveal melanoma (Combination therapy, First-line therapy, Metastatic disease)